跳至主要内容
临床试验/CTRI/2021/04/032550
CTRI/2021/04/032550尚未招募未知

A Randomised Controlled study of efficacy and safety of Saroglitazar in Type 2 Diabetis Mellitus

AIIMS Jodhpur0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募
发起方
AIIMS Jodhpur

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age 18 â?? 65yr.
  • 2.Diagnosis of type 2 diabetes mellitus as per ADA criteria.
  • 3.On lifestyle modifications and on metformin; vildagliptin medications for 3 months.
  • 4.HbA1C >7%

排除标准

  • 1.Patient who had any clinically significant or unstable medical or Psychiatric illness.
  • 2.History of cardiac diseases (NYHA grade 3 â?? 4) or cardiac anomalies.
  • 3.Patient on glitazone/glitazar for >30days.
  • 4.History of Renal insufficiency - serum creatinine >=1.8mg/dl.
  • 5.Patient with history of significant hepatic impairment (serum bilirubin >2 times, AST, ALT and alkaline phosphatase >3 times the upper limit of normal).
  • 6.Patient have history of uncontrolled hypertension.
  • 7.Patient have any malignancy and Patient have any h/o substance abuse (alcohol/drugs).
  • 8.Pregnant & Lactating Woman and Patient with history of allergy/intolerance.

研究者

发起方
AIIMS Jodhpur

相似试验